1-13 of 13
Zofia Piotrowska
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes

Available to Purchase
Catherine B. Meador, Subba R. Digumarthy, Beow Y. Yeap, Yin P. Hung, Mari Mino-Kenudson, Anna F. Farago, Rebecca S. Heist, J. Paul Marcoux, Deepa Rangachari, David A. Barbie, Zofia Piotrowska
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 25–34.
https://doi.org/10.1158/1078-0432.CCR-24-2350
Published: 06 January 2025
View articletitled, Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
Open the PDF for Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes in another window
Includes: Supplementary data
Journal Articles

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer

Open Access
Daniel Morgensztern, Neal Ready, Melissa L. Johnson, Afshin Dowlati, Noura Choudhury, David P. Carbone, Eric Schaefer, Susanne M. Arnold, Sonam Puri, Zofia Piotrowska, Aparna Hegde, Anne C. Chiang, Wade Iams, Anthony Tolcher, Kaname Nosaki, Toshiyuki Kozuki, Tianhong Li, Rafael Santana-Davila, Hiroaki Akamatsu, Haruyasu Murakami, Hiroshi Yokouchi, Song Wang, Jiuhong Zha, Rui Li, Randy R. Robinson, Pooja Hingorani, Edwin E. Jeng, Muhammad Furqan
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5042–5052.
https://doi.org/10.1158/1078-0432.CCR-24-1547
Published: 15 November 2024
View articletitled, A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Open the PDF for A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

Open Access
Talal El Zarif, Catherine B. Meador, Xintao Qiu, Ji-Heui Seo, Matthew P. Davidsohn, Hunter Savignano, Gitanjali Lakshminarayanan, Heather M. McClure, John Canniff, Brad Fortunato, Rong Li, Mandeep K. Banwait, Karl Semaan, Marc Eid, Henry Long, Yin P. Hung, Navin R. Mahadevan, David A. Barbie, Matthew G. Oser, Zofia Piotrowska, Toni K. Choueiri, Sylvan C. Baca, Aaron N. Hata, Matthew L. Freedman, Jacob E. Berchuck
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3798–3811.
https://doi.org/10.1158/1078-0432.CCR-24-0466
Published: 03 September 2024
View articletitled, Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Open the PDF for Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling in another window
Includes: Supplementary data
Journal Articles

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Available to Purchase
Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Christina Nguyen, Manali Phadke, Fang-Yong Li, Joel Neal, Mark A. Lemmon, Zenta Walther, Katerina Politi, Sarah B. Goldberg
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (11): 2123–2130.
https://doi.org/10.1158/1078-0432.CCR-22-3497
Published: 01 June 2023
View articletitled, Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Open the PDF for Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations in another window
Includes: Supplementary data
Journal Articles

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Available to Purchase
Erin M. Bertino, Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, Christine Hann, Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie L. Lau, Lynette Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1604–1611.
https://doi.org/10.1158/1078-0432.CCR-20-4084
Published: 15 March 2021
View articletitled, Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
Open the PDF for Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903) in another window
Includes: Supplementary data
Journal Articles

Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue

Available to Purchase
Zofia Piotrowska, Aaron N. Hata
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2441–2443.
https://doi.org/10.1158/1078-0432.CCR-20-0097
Published: 01 June 2020
View articletitled, Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
Open the PDF for Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue in another window
Journal Articles

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Free
Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2277.
https://doi.org/10.1158/1078-0432.CCR-20-0939
Published: 01 May 2020
View articletitled, Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Open the PDF for Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas in another window
Journal Articles

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Free
Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6548–6555.
https://doi.org/10.1158/1078-0432.CCR-18-1541
Published: 13 December 2018
View articletitled, EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Open the PDF for EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas in another window
Includes: Supplementary data
Journal Articles

Abstract PR04: Decoding tumor microenvironment to enhance NSCLC targeted therapy

Free
Haichuan Hu, Lecia Sequist, Zofia Piotrowska, Hillary Mulvey, Sundus Noeen, Patricia Hare, David Kodack, Aaron Hata, Matt Niederst, Cyril Benes, Jeff Engelman
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): PR04.
https://doi.org/10.1158/1557-3265.AACRIASLC18-PR04
Published: 01 September 2018
View articletitled, Abstract PR04: Decoding tumor microenvironment to enhance NSCLC targeted therapy
Journal Articles

Abstract B25: Decoding tumor microenvironment to enhance NSCLC targeted therapy

Free
Haichuan Hu, Lecia Sequist, Zofia Piotrowska, Hillary Mulvey, Sundus Noeen, Patricia Hare, David Kodack, Aaron Hata, Matt Niederst, Cyril Benes, Jeff Engelman
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): B25.
https://doi.org/10.1158/1557-3265.AACRIASLC18-B25
Published: 01 September 2018
View articletitled, Abstract B25: Decoding tumor microenvironment to enhance NSCLC targeted therapy
Journal Articles

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

Free
Kyung-A Song, Matthew J. Niederst, Timothy L. Lochmann, Aaron N. Hata, Hidenori Kitai, Jungoh Ham, Konstantinos V. Floros, Mark A. Hicks, Haichuan Hu, Hillary E. Mulvey, Yotam Drier, Daniel A.R. Heisey, Mark T. Hughes, Neha U. Patel, Elizabeth L. Lockerman, Angel Garcia, Shawn Gillepsie, Hannah L. Archibald, Maria Gomez-Caraballo, Tara J. Nulton, Brad E. Windle, Zofia Piotrowska, Sinem E. Sahingur, Shirley M. Taylor, Mikhail Dozmorov, Lecia V. Sequist, Bradley Bernstein, Hiromichi Ebi, Jeffrey A. Engelman, Anthony C. Faber
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (1): 197–208.
https://doi.org/10.1158/1078-0432.CCR-17-1577
Published: 02 January 2018
View articletitled, Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
Open the PDF for Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM in another window
Includes: Supplementary data
Journal Articles

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Free
Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Xiujun Fu, Christopher G. Azzoli, Zofia Piotrowska, Tiffany G. Huynh, Ling Zhao, Linnea Fulton, Katherine R. Schultz, Emily Howe, Anna F. Farago, Ryan J. Sullivan, James R. Stone, Subba Digumarthy, Teresa Moran, Aaron N. Hata, Yukako Yagi, Beow Y. Yeap, Jeffrey A. Engelman, Mari Mino-Kenudson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (18): 4585–4593.
https://doi.org/10.1158/1078-0432.CCR-15-3101
Published: 15 September 2016
View articletitled, EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Open the PDF for EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis in another window
Includes: Supplementary data
Journal Articles

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Free
Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey, Elizabeth L. Lockerman, Angel R. Garcia, Zofia Piotrowska, Lecia V. Sequist, Jeffrey A. Engelman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (17): 3924–3933.
https://doi.org/10.1158/1078-0432.CCR-15-0560
Published: 31 August 2015
View articletitled, The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Open the PDF for The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies in another window
Includes: Supplementary data